Kunwar S, et al. - Experts conducted a meta-analysis to evaluate the overall safety and effectiveness of baricitinib (an oral, selective Janus kinase 1 and 2 inhibitor) in RA. Relevant English-language studies were found via a search of PubMed, EMBASE, and Cochrane CENTRAL from beginning through September 24, 2017. When compared to placebo, 4 mg of baricitinib did not increase the risk of serious adverse events, but herpes zoster infection was increased. Results of this study suggested that baricitinib is efficacious in the treatment of RA and did not seem to have significant safety concerns during the initial 6 months of treatment.